ADCT
ADC Therapeutics S.A.
NYSE · Healthcare · Biotechnology · CH
$1.35
+1.89%Aug 13, 2026, 12:00 UTC
ADC Therapeutics submitted abstracts for LOTIS-5, LOTIS-7, and MZL IIT data for presentation at the 68th ASH Annual Meeting and Exposition.
Source:Aug 13, 2026, 12:00 UTC
ADC Therapeutics held a pre-sBLA meeting with the U.S. FDA to discuss LOTIS-5 data and is assessing the regulatory path for full approval of ZYNLONTA.
Source:Aug 13, 2026, 12:00 UTC
ADC Therapeutics reported second quarter 2026 financial results, with net product revenue of $18.6 million and cash and cash equivalents of $219.1 million as of June 30, 2026.
Jun 5, 2026, 00:00 UTC
AbCellera Biologics Inc. appointed Victor Sandor as a Director, effective June 1, 2026.
Jun 4, 2026, 12:02 UTC
ADC Therapeutics shares slumped nearly 53% in premarket trading after a late-stage study of its blood cancer drug showed more deaths among treated patients.
Source: